Revitalist Publishes Proprietary Diagnostic Tool After Receiving Certificate of Registration from The United States… Jan 27, 2022
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program… Jan 6, 2022
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key… Jan 4, 2022
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine)… Dec 15, 2021
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights Dec 15, 2021
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent… Dec 14, 2021